Rostock, Germany-based Centogene AG has unveiled a 24-month global study to look at the genetic factors in Parkinson's disease (PD), which affects about 1% of individuals older than 60. Specifically, the Rostock International Parkinson's Disease (ROPAD) study, which will involve up to 10,000 patients, will investigate the genetic background of PD patients for a better understanding of disease development, diagnosis, and treatment.